Genotyping for severe drug hypersensitivity

Current Allergy and Asthma Reports

Volumn 14, Issue 3, 2014, Pages

  Karlin, Eric ^a   Phillips, Elizabeth ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MURDOCH UNIVERSITY   (Australia)

Author keywords

Altered peptide repertoire; DILI; DRESS; Drug hypersensitivity; Genotyping; Human leukocyte antigen; Major histocompatibility complex; Pharmacogenetics; Pharmacogenomics; SCAR; Stevens Johnson syndrome; Toxic epidermal necrolysis; Translation

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAMAZEPINE; FLUCLOXACILLIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B15 ANTIGEN; HLA B57 ANTIGEN; NEVIRAPINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; HLA B ANTIGEN;

CLINICAL PRACTICE; DRESS SYNDROME; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG SAFETY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOPATHOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PHARMACOGENOMICS; REVIEW; SOUTHEAST ASIA; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; CHEMISTRY; ETHNOLOGY; GENETICS; IMMUNOLOGY; PHARMACOGENETICS; PROTEIN CONFORMATION;

ALLOPURINOL; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CARBAMAZEPINE; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; GENOTYPE; HLA-B ANTIGENS; HUMANS; NEVIRAPINE; PHARMACOGENETICS; PROTEIN CONFORMATION; STEVENS-JOHNSON SYNDROME;

EID: 84891894586     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0418-0     Document Type: Review

References (110)

1. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017-25.
2. Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay - a systematic review. Eur J Clin Pharmacol. 2013.
3. Suh DC et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34(12):1373-9.
4. Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9. (Pubitemid 38869995)
5. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285-306.
6. Schnyder B et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest. 1997;100(1):136-41. (Pubitemid 27311251)
7. Zanni MP et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest. 1998;102(8):1591-8. (Pubitemid 28492227)
8. Zanni MP et al. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta + T cell clones. Int Immunol. 1998;10(4):507-15. (Pubitemid 28182108)
9. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683-93.
10. Bharadwaj M et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol. 2012;52:401-31.
11. •• Norcross MA et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012;26(11):F21-9. Using abacavir-treated HLA-B*57: 01 B-cell lines, the authors demonstrated additional evidence that abacavir alters the quantity and quality of self-peptide loading into HLA-B*57:01.
12. •• Wei CY et al. Direct interaction between HLA-B and carbamazepine activates Tcells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562-9 e5. This article demonstrates a direct interaction of HLA molecules with drugs and provides a potential mechanism for HLA-associated drug hypersensitivity reactions. Supportive of altered peptide repertoire model for carbamazepine.
13. •• Illing PT et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554-8. Study supporting the altered peptide repertoire model for abacavir hypersensitivity. Abacavir associates with HLA-B*57:01 non-covalently and alters the shape and chemistry of the antigen-binding cleft. This leads to an altered repertoire of endogenous peptides binding HLA-B*57:01. The crystal structure of abacavir-MHC-peptide was resolved using an endogenous peptide. Preliminary evidence to support the altered peptide repertoire model for was also presented.
14. •• Ostrov DA et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012;109(25):9959-64. Provided structural, biochemical and functional evidence for non-covalent interaction between abacavir and HLA-B*57:01 and the altered repertoire model for abacavir. A synthetic peptide was derived that binds to HLA-B*57:01 only in the presence of abacavir. The crystal structure of abacavir-MHC-peptide was resolved using this peptide.
15. Cutrell AG et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38(12):2171-2. (Pubitemid 40169396)
16. Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read. 2001;11(4):222-6. (Pubitemid 32332270)
17. Symonds W et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24(4):565-73. (Pubitemid 34492878)
18. Mallal S et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-32. (Pubitemid 34215071)
19. Hetherington S et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121-2. (Pubitemid 34270738)
20. Hughes AR et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5(2):203-11. (Pubitemid 38351278)
21. Saag M et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111-8. (Pubitemid 351589880)
22. Mallal S et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-79. (Pubitemid 351214284)
23. Schackman BR et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025-33.
24. Rauch A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99-102. (Pubitemid 43939082)
25. Guo Y et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci. 2013;56(2):119-24.
26. Chessman D et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;28(6):822-32. (Pubitemid 351784513)
27. •• Adam J et al. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol. 2012;42(7):1706-16. Paper providing evidence that abacavir interacts with HLA-B*57:01 in a non-covalent and metabolism-independent fashion. Additionally, this study provided evidence that abacavir-reactive T-cell clones are dependent on the drug concentration, TCR avidity and level of HLA-B*57:01 molecules expressed on APCs.
28. Knowles SR, Dewhurst N, Shear N. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767-78.
29. • McCormack M et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-43. First GWAS for carbamazepine in Europeans that identified an association with HLA-A*31:01 and individuals of northern European ancestry with various phenotypes of carbamazepine-induced hypersensitivity reactions. Although this study suggested an association between HLA-A*31:01 and carbamazepine SJS/TEN in European populations, not all follow-up studies have supported this.
30. Chung WH et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
31. Kulkantrakorn K et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract. 2012;12(3):202-8.
32. Mehta TY et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75(6):579-82.
33. Then SM et al. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol. 2011;29(3):290-3.
34. Man CB et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015-8. (Pubitemid 46763406)
35. Wang Q et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011;20(6):446-8.
36. Zhang Y et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2011;67(9):885-7.
37. Chen P et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126-33.
38. • Ko TM et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266-76. Important in vitro study that establishes the essential role of the TCR in the mechanism behind SJS/TEN and explains why some HLA-B*15:02 carriers are tolerant to carbamazepine.
39. Mizumoto K et al. Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A*3101. J Dermatol. 2012;39(9):791-2.
40. Niihara H et al. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39(7):594-601.
41. • Ozeki T et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034-41. GWAS that showed association with HLA-A*31:01 and carbamazepine-induced immunologically mediated adverse drug reactions in those of Japanese ancestry.
42. Yip VL et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012;92(6):757-65.
43. Amstutz U et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013;94(1):142-9.
44. Ramasamy SN et al. Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950-2012. Drug Saf. 2013.
45. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64(2):229-58.
46. Lang Jr PG. Severe hypersensitivity reactions to allopurinol. South Med J. 1979;72(11):1361-8.
47. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391-5.
48. Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica. 1989;179(1):32-3. (Pubitemid 19172335)
49. Hung SI et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-9.
50. Dainichi T et al. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215(1):86-8. (Pubitemid 46976024)
51. Kaniwa N et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617-22.
52. Tassaneeyakul Wet al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704-9.
53. Jung JW et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011;26(11):3567-72.
54. Kang HR et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303-7.
55. Lonjou C et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99-107.
56. Genin E et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis. 2011;6:52.
57. Tohkin M et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13(1):60-9.
58. Somkrua R et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.
59. Pompeu YA et al. The structural basis of HLA-associated drug hypersensitivity syndromes. Immunol Rev. 2012;250(1):158-66.
60. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20(6):1071-92. (Pubitemid 29058411)
61. Gangar M et al. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother. 2000;34(7-8):839-42. (Pubitemid 30471262)
62. Martin AM et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19(1):97-9. (Pubitemid 40111026)
63. •• Yuan J et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011;25(10):1271-80. Genetic study investigating different clinical presentations of nevirapine hypersensitivity and reporting several new associations with specific HLA alleles.
64. Vitezica ZG et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22(4):540-1. (Pubitemid 351317299)
65. •• Phillips E et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e55-7. A class II allele DRB1*01:02 which is homologous to DRB1*01:01 is related to nevirapine-associated hepatitis in South African Black populations.
66. Littera R et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20(12):1621-6. (Pubitemid 44162404)
67. Gatanaga H et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21(2):264-5. (Pubitemid 46036947)
68. Gao S et al. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. AIDS Res Hum Retroviruses. 2012;28(6):540-3.
69. Chantarangsu S et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19(2):139-46.
70. Chantarangsu S et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis. 2011;53(4):341-8.
71. Likanonsakul S et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther. 2009;6:22.
72. •• Carr DF et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis. 2013;56(9):1330-9. First study to associate HLA-C*04:01 with nevirapine-associated Stevens-Johnson Syndrome/Toxic epidermal necrolysis in a Black African population.
73. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116-26.
74. Hautekeete ML et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology. 1999;117(5):1181-6. (Pubitemid 29512678)
75. O'Donohue J et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717-20.
76. Donaldson PT et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010;53(6):1049-53.
77. Lucena MI et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338-47.
78. Lucena MI et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850-6. (Pubitemid 46489548)
79. Stephens C et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8(7):e68111.
80. Olsson R et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15(1-2):154-61.
81. Russmann S et al. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol. 2005;60(1):76-82. (Pubitemid 40942784)
82. Daly AK et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816-9.
83. Phillips EJ, Mallal SA. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. AIDS. 2013;27(3):491-2.
84. Ferrell Jr PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543-6.
85. Phillips EJ et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19(9):979-81. (Pubitemid 40834943)
86. Shear NH et al. A review of drug patch testing and implications for HIV clinicians. AIDS. 2008;22(9):999-1007. (Pubitemid 351769738)
87. Phillips EJ et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002;16(16):2223-5. (Pubitemid 35387279)
88. Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis. 2003;48(3):137-9. (Pubitemid 36683480)
89. Buyuktiryaki AB et al. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. Australas J Dermatol. 2012;53(4):274-7.
90. Lin YT, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2012.
91. Phillips EJ, Mallal SA. HLA-B*1502 screening and toxic effects of carbamazepine. N Engl J Med. 2011;365(7):672. author reply 673.
92. Martin AM et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;101(12):4180-5. (Pubitemid 38405903)
93. Hammond E et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther. 2007;12(7):1027-32. (Pubitemid 350114982)
94. Martin AM et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics. 2006;16(5):353-7.
95. Melis R et al. Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. Genet Test Mol Biomarkers. 2012;16(9):1111-4.
96. Zhang FR et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620-8.
97. Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E. Fever, rash and systemic symptoms: understanding the role of virus and HLA in cutaneous drug allergy. J Allerg Clin Immunol In Practice. 2014;2(1):21-33.
98. Kim SH et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97(1-2):190-7.
99. Kaniwa N et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461-5.
100. Ikeda H et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51(2):297-300.
101. Hung SI et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349-56.
102. Lin LC et al. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J Med Sci. 2009;25(2):82-6.
103. Cheung YK et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307-14.
104. Locharernkul C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087-91.
105. Kaniwa N et al. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013;14(15):1821-31.
106. Kim SH et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010;11(6):879-84.
107. Alfirevic A et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;7(6):813-8. (Pubitemid 44446732)
108. Singer JB et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711-4.
109. Kindmark A et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186-95. (Pubitemid 351712643)
110. Spraggs CF et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667-73.